Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.47
+0.06 (0.94%)
At close: Oct 21, 2025, 4:00 PM EDT
6.35
-0.12 (-1.85%)
After-hours: Oct 21, 2025, 6:02 PM EDT
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$52,932
Profits / Employee
-$2,542,366
Market Cap
108.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
COYA News
- 14 days ago - Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function - Business Wire
- 22 days ago - Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - PRNewsWire
- 4 weeks ago - Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis - PRNewsWire
- 5 weeks ago - Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model - PRNewsWire
- 6 weeks ago - Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial - PRNewsWire
- 6 weeks ago - PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies - GlobeNewsWire
- 6 weeks ago - Coya Therapeutics to Participate at Upcoming September Investor Conferences - PRNewsWire
- 2 months ago - Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - PRNewsWire